Exacerbation of chronic hepatitis D during interferon alpha administration

Acute and severe impairment of liver function with jaundice and ascites occ urred in two out of seven patients with chronic hepatitis D during interfer on alpha administration (10 MU three times a week). Both of them were young women with histological diagnoses of moderate to severe chronic hepatitis and cirrhosis with no signs of portal hypertension. Only a slow and partial recovery observed after interferon withdrawal. Autoantibodies against basa l cell layer tested positive in these two patients. In the remaining five p atients with hepatitis D who did not experience liver impairment during int erferon administration, basal cell layer antibodies were found only in one case. We conclude that severe decompensation of liver cirrhosis related to hepatitis D may occur during interferon administration. Positivity of basal cell layer antibodies may be associated with the risk of developing such a n adverse event but our data are trot sufficient to prove this association.